GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured. GRAIL is focused on saving lives and improving health by pioneering new technologies for early cancer detection. The company uses the power of next-generation DNA sequencing, population-scale clinical studies, and state-of-the-art computer and data science to overcome one of medicine’s greatest challenges. Their first product, the Galleri™ multi-cancer early detection test, complements guideline-recommended screenings, and can detect more than 50 types of cancer through a routine blood draw. When cancer is detected, the Galleri test can predict the cancer signal origin with high accuracy. For more information visit GRAIL.com.